Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
EMAN
3301
DELISTED
eMagin Corporation
EMAN
| $79K | ﹤0.01% |
99,800
-168,411
| -63% | -$88.6K |
2019 Q1
5 quarters
|
|
3302
Boxlight
BOXL
$2.81M
| $77K | ﹤0.01% |
58
+46
| +383% | +$52.7K |
2019 Q4
2 quarters
|
|
|
IMV
3303
DELISTED
IMV Inc. Common Shares
IMV
| $77K | ﹤0.01% |
+2,460
| New | +$61.9K |
2020 Q2
0 quarters
|
|
3304
Rekor Systems
REKR
$45.4M
| $76K | ﹤0.01% |
+18,932
| New | +$67.9K |
2020 Q2
0 quarters
|
|
|
NMTR
3305
DELISTED
9 Meters Biopharma
NMTR
| $74K | ﹤0.01% |
6,440
-4,830
| -43% | -$54.5K |
2019 Q4
2 quarters
|
|
|
DNR
3306
DELISTED
Denbury Resources, Inc.
DNR
| $72K | ﹤0.01% |
+261,635
| New | +$78.6K |
2020 Q2
0 quarters
|
|
3307
Avalon Holdings
AWX
$10.3M
| $71K | ﹤0.01% |
44,000
+10,900
| +33% | +$15.8K |
2019 Q4
2 quarters
|
|
3308
SEACOR Marine Holdings
SMHI
$237M
| $70K | ﹤0.01% |
27,546
-10,115
| -27% | -$28.8K |
2019 Q2
4 quarters
|
|
3309
Banco Bradesco
BBDO
$40.6B
| $69K | ﹤0.01% |
24,033
+6,087
| +34% | +$17.4K |
2020 Q1
1 quarter
|
|
3310
Forum Energy Technologies
FET
$979M
| $69K | ﹤0.01% |
6,555
-30,716
| -82% | -$246K |
2018 Q2
8 quarters
|
|
|
JFIN
3311
Jiayin Group
JFIN
$69.1M
| $69K | ﹤0.01% |
+17,758
| New | +$50.5K |
2020 Q2
0 quarters
|
|
3312
CBAK Energy Technology Ltd
CBAT
$94M
| $68K | ﹤0.01% |
88,989
-2,260
| -2% | -$1.19K |
2019 Q1
5 quarters
|
|
|
BDRX
3313
Biodexa Pharmaceuticals
BDRX
$469K
| – | – |
0
| – | – |
2019 Q4
2 quarters
|
|
|
CASI
3314
DELISTED
CASI Pharmaceuticals
CASI
| $67K | ﹤0.01% |
+2,680
| New | +$58.2K |
2020 Q2
0 quarters
|
|
3315
CLPS Inc
CLPS
$30.1M
| $67K | ﹤0.01% |
+30,816
| New | +$63.9K |
2020 Q2
0 quarters
|
|
|
PME
3316
DELISTED
Pingtan Marine Enterprise Ltd.
PME
| $66K | ﹤0.01% |
+57,287
| New | +$61.7K |
2020 Q2
0 quarters
|
|
|
KRKR
3317
36Kr Holdings
KRKR
$6.02M
| $64K | ﹤0.01% |
+964
| New | +$82.9K |
2020 Q2
0 quarters
|
|
|
HURA
3318
TuHURA Biosciences
HURA
$126M
| $63K | ﹤0.01% |
52
+45
| +643% | +$57.6K |
2019 Q4
2 quarters
|
|
3319
Ocugen
OCGN
$319M
| $62K | ﹤0.01% |
279,669
-407,845
| -59% | -$123K |
2019 Q4
2 quarters
|
|
|
BSIN
3320
Big Sky Industrial
BSIN
$77.7M
| $62K | ﹤0.01% |
+12,060
| New | +$59.7K |
2020 Q2
0 quarters
|
|
|
GMO
3321
DELISTED
General Moly, Inc.
GMO
| $62K | ﹤0.01% |
306,741
+268,846
| +709% | +$53.2K |
2017 Q1
13 quarters
|
|
3322
Geron
GERN
$797M
| $61K | ﹤0.01% |
+28,176
| New | +$42.1K |
2020 Q2
0 quarters
|
|
|
RKTO
3323
Rocket One Inc
RKTO
$16.5M
| $61K | ﹤0.01% |
+950
| New | +$74.3K |
2020 Q2
0 quarters
|
|
3324
Siebert Financial
SIEB
$90.8M
| $61K | ﹤0.01% |
12,100
+700
| +6% | +$4.42K |
2020 Q1
1 quarter
|
|
3325
Paramount Gold Nevada
PZG
$101M
| $60K | ﹤0.01% |
+48,180
| New | +$51.5K |
2020 Q2
0 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.